Asset Details
Do you wish to reserve the book?
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation
Do you wish to request the book?
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation
2024
Overview
Autologous stem cell transplantation (autoHCT) is considered standard of care for newly diagnosed multiple myeloma (MM). Although most patients eventually progress after autoHCT, a small proportion achieve a durable response. In this retrospective study we included 1576 patients, 244 (15%) of whom were long-term responders (LTR), defined as having a progression-free survival (PFS) of ≥8 years after transplant. Patients in the LTR group were younger than the non-LTR group (median age 58.4 vs. 59.5 years;
p
= 0.012), less likely to have high-risk cytogenetics (4% vs. 14%;
p
< 0.001), more often had <50% bone marrow plasma cells (67% vs. 58%;
p
= 0.018) and R-ISS stage I disease (43% vs. 34%). More patients in the LTR group received post-transplant maintenance (63% vs. 52%;
p
= 0.002). Patients in the LTR group had higher rates of complete response (CR) at day100 (41% vs. 27%;
p
< 0.001) and at best post-transplant response (70% vs. 37%;
p
< 0.001), compared to the non-LTR group. Patients in the LTR groups had a median PFS of 169.3 months and the median overall survival (OS) had not been reached. The leading cause of death in the LTR was disease progression. In conclusion, 15% of patients in the cohort were LTR after upfront autoHCT, with distinct characteristics and a median PFS of more than 14 years.
Publisher
Nature Publishing Group UK,Springer Nature B.V,Nature Publishing Group
